Full-Time

Software Developer 3

iOS Development

Posted on 10/3/2025

Dexcom

Dexcom

5,001-10,000 employees

Markets real-time CGM devices and analytics

Compensation Overview

$116.6k - $194.4k/yr

Company Does Not Provide H1B Sponsorship

Remote in USA

Remote

Category
Software Engineering (1)
Required Skills
Kotlin
Agile
Git
JIRA
Jenkins
iOS/Swift
Confluence
Requirements
  • Bachelor’s degree in computer science or related field.
  • Minimum 2 years of native iOS app development experience using Kotlin and Jetpack Compose and 5 years of professional software development experience.
  • High degree of diligence in documentation, testing and coding.
  • Experience working in Agile teams & using tools such as Jira and Confluence.
  • Experience using CI/CD tools such as Jenkins, Bamboo, Github Actions.
  • Experience with version control tools such as Git, Github, Gitlab, Bitbucket and GitFlow.
  • Experience writing automated tests.
  • Working knowledge of design patterns such as MVC, MVVM, MVP.
Responsibilities
  • Design and build applications for the iOS platform.
  • Implement requirements on iOS apps, write and update design documents.
  • Continuously discover, evaluate and implement new technologies to strengthen development efficiency.
  • Interface with software test to ensure high quality product.
  • Develop automated unit and integration tests.
  • Participate in design, code and test reviews, provide technical leadership.
  • Propose and implement enhancements to the apps to improve sustainability.
Desired Qualifications
  • Typically requires a Bachelor’s degree in a technical discipline, and a minimum of 5-8 years related experience or Master’s degree and 2-5 years equivalent industry experience or a PhD and 0-2 years experience.

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • G7 rollout converts 50% of base by 2026 year-end, expanding margins to 64%.
  • Prime Therapeutics covers 7 million type 2 patients by December 2026.
  • International revenue surges 26% YoY in Q1 2026 from Europe reimbursements.

What critics are saying

  • Abbott FreeStyle Libre erodes Dexcom's US market share through lower prices.
  • G6 discontinuation on July 1, 2026, triggers customer churn to competitors.
  • CMS competitive bidding slashes Dexcom's Medicare pricing in 2027.

What makes Dexcom unique

  • Dexcom G7 offers 15-day wear time versus competitors' 10-14 days.
  • Dexcom Clarity software provides trend analysis proven to lower A1C.
  • Dexcom Share enables real-time glucose sharing with up to 10 followers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
John Paul Construction
Mar 30th, 2026
Dexcom - project completion.

Dexcom - project completion. Date: March 30, 2026 John Paul Construction Limited is pleased to mark the completion of the Dexcom Medical Devices Facility, a state of the art manufacturing and office development delivered over a 25-month programme. The facility includes a highly technical production environment with cleanrooms, supporting laboratory and engineering spaces, alongside a four-storey office building. As Dexcom's first manufacturing facility outside of the United States, the project represents a significant milestone for the company's global expansion. Once operational, it will develop and manufacture real time continuous glucose monitoring systems, supporting diabetes management, and improving patient outcomes globally. This project was particularly important to its team, reflecting its capability in delivering complex, high specification life sciences facilities, with a strong focus on quality, safety, and programme certainty. From a sustainability perspective, the project excavated and successfully retained 170,000m^3 of subsoil and topsoil, planted 600 native Irish Oak trees as part of the Athenry Tidy Towns initiative, and is submitting for LEED Gold certification. A strong local supply chain was also central to the success of the project, supporting both delivery and the wider regional economy. Dexcom has been a valued client throughout, and John Paul Construction Limited appreciate the trust placed in John Paul Construction Limited to deliver this significant investment. John Paul Construction Limited would like to thank the design team, its project partners and the wider site team for their commitment and professionalism in bringing this project to completion.

Healthcare Asia Magazine
Mar 27th, 2026
Dexcom Malaysia wins at Healthcare Asia Medtech Awards 2026 for automation.

Dexcom Malaysia wins at Healthcare Asia Medtech Awards 2026 for automation. Automation enhances manufacturing efficiency and employee safety across Dexcom Malaysia's operations. Dexcom Malaysia won the Automation Initiative Award - Malaysia in the Healthcare Asia Medtech Awards 2026. The Automated Material Handler System features an Autonomous Mobile Robot (AMR) alongside vertical lifters and conveyors, creating a fully automated route for moving palletised products across a 550-meter span from production areas to the warehouse. By removing the need for employees to manually transport heavy loads, the system significantly reduces physical strain and enhances overall safety on the production floor. Dexcom Malaysia followed a phased approach for rollout. The team started with small-scale pilot runs to test and refine the system. They then scaled it up across operations. The strategy targeted key areas to lower costs, raise efficiency, and improve ergonomics. The AMR itself is engineered to carry loads of up to 650 kg and is equipped with an array of sensors and vision-based navigation technologies. These capabilities enable the robot to move autonomously, avoid collisions, and operate safely alongside people. The system also includes a pallet lifter that automatically raises and lowers pallets for pick-up and drop-off, eliminating risky manual handling steps during palletising. Join Healthcare Asia Magazine community A staging conveyor holds up to 26 pallets across dual lanes, functioning as an intermediate buffer before the next processing stage. By automating these repetitive and time-intensive tasks, employees are freed to focus on higher-value activities. Production floors gain space as finished goods pallets move straight out after palletising. This creates a cleaner, more spacious, and more efficient operating environment. The system's modular architecture means it can easily scale as production grows - new routes, stations, or tasks can be added through simple reprogramming rather than major infrastructure changes. The AMRs use safety-rated sensors to ensure controlled, collision-free movement, whilst automation removes many of the ergonomic risks previously associated with manual pallet transfers. The continuous, uninterrupted operation of the system also reduces idle time and smooths overall workflow, contributing to higher throughput and more consistent production performance. The Healthcare Asia Medtech Awards honours the most exemplary medtech companies across Asia. It serves as a platform for organisations to showcase their pioneering medical devices, life-saving software, or top-notch healthcare solutions, amongst other innovations. The Healthcare Asia Medtech Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be acclaimed for your organisation's initiatives and contribution to enhancing the industry's overall performance, please contact Julie Anne Nuñez-Difuntorum at [email protected].

Yahoo Finance
Mar 23rd, 2026
DexCom analyst targets diverge as Barclays cuts to $71 amid Abbott competition concerns

DexCom's fair value estimate has been adjusted to $86.12 per share, whilst analyst price targets range from the low $70s to mid $80s, reflecting differing views on competition in the continuous glucose monitoring market. Citi and Bernstein recently raised their targets to $84 and $86 respectively, with several firms including Baird, Mizuho and Barclays revising models upward. However, Barclays assigned an Underweight rating with a $71 target, citing concerns over market share pressure from Abbott's Freestyle Libre platform. DexCom completed a $500 million share repurchase programme, buying back nearly 2% of shares. The company reiterated fiscal 2026 revenue guidance of $5.16 billion to $5.25 billion and announced AI-enabled upgrades to its Stelo app.

Springboard Pro Ltd
Mar 17th, 2026
An toileán beannaithe ina mórchumhacht medtech.

An toileán beannaithe ina mórchumhacht medtech. 17 March 2026 Every year on St Patrick's Day, the world celebrates Ireland - its heritage, its people, its resilience. But beyond the parades, music, and tropes, the Emerald Isle has another story worth telling: Ireland, both North and South, has become one of the world's most dynamic, collaborative, and fast-growing clusters for medical technology, drug-delivery, digital health and advanced manufacturing. In short, its nuts. For global innovators and scaling device companies, this island is more than a symbol of good fortune, it's a strategic location supported by academic excellence, strong research ecosystems, and cross-border cooperation. The North - a rising force in Medtech & Drug Delivery Northern Ireland holds an extraordinary position as the only region in the world with seamless access to both EU and GB markets, removing customs barriers and smoothing regulatory and commercial pathways for medtech developers. Queen's University Belfast & Ulster University: Twin Academic Powerhouses Queen's University Belfast (QUB) is home to major infrastructure like the Future Medicines Institute, a £55M initiative accelerating device innovation, diagnostics and precision medicine. One standout example is Re-Vana Therapeutics, a QUB spin-out that secured a landmark $1B collaboration with Boehringer Ingelheim to advance long-acting ophthalmic drug-delivery systems an achievement that puts Northern Ireland firmly on the global map of drug-delivery innovation. Something I am immensely proud to see. Ulster University is an essential partner in NI's life-sciences ecosystem, contributing expertise in digital healthcare technology, AI, medical-device R&D, and biomolecular innovation through its Centre for Digital Healthcare Technology and participation in the Future Medicines Institute. Catalyst: North-South Collaboration at Scale Catalyst - the leading NI innovation hub - runs ONEHEALTH, a €10M cross-border programme uniting partners such as QUB, University of Galway, Tyndall Institute and others. The initiative focuses on AI-driven diagnostics, digital health, medtech and agrifood technologies, while supporting SMEs and enabling 12 cross-border R&D programmes over four years. The South: "A global medtech powerhouse" or "Europe's MedTech Export Giant" Ireland is Europe's second-largest exporter of medtech, contributing over €16 billion annually, representing 14% of all Irish exports. With over 300 medtech companies, 50,000+ employees, and 14 of the world's top 15 medtech manufacturers present, the country is uniquely positioned as a global manufacturing and R&D leader. Unprecedented Investment & Innovation GE Healthcare's €132M expansion in Cork, record VC dealmaking, and Galway's role as the "Silicon Valley of MedTech" all point to a thriving innovation ecosystem. Dexcom's decision to establish its first European manufacturing hub in Athenry, Co. Galway marks one of the largest private-sector investments ever seen in the region - €300M over five years, creating 1,000+ high-skill jobs. The 180,000-sq-ft state-of-the-art facility is designed to manufacture millions of continuous glucose monitoring (CGM) sensors annually, addressing surging demand across Europe, the Middle East and Africa. This move strengthens the West of Ireland's already elite MedTech cluster and further positions the country as a leader in diabetes-care technology. I don't need to inform anyone on Stryker, Medtronic or Boston, all of whom continue to invest, grow and develop. EY reports global MedTech revenue reached US$584B in 2025, continuing seven years of growth, with venture funding surging 16%. Ireland plays a major role in high-growth areas like diabetes-delivery, structural heart, and robotics. Sanner's CDMO offering aligns closely with Ireland's academic excellence, global commercial reach and cross-border cooperation. 1. Drug-Device Combination Expertise With breakthroughs coming from QUB and Irish innovators in long-acting and controlled-release systems, Sanner provides the engineering, moulding, sealing, testing and regulatory know-how needed to industrialise complex drug-delivery platforms. 2. Precision Components for High-Growth MedTech Sectors Combination devices, inhalation systems, diagnostics housings and more - Sanner has deep expertise. 3. Ideal Partner for Innovators & Scaling SMEs Ireland's 400+ medtech and health-tech companies need CDMO partners capable of iterative development and scale - Sanner's development model fits these needs. 4. Digital-Health-Ready Device Housings Catalyst's emphasis on AI, sensors and digital health aligns with Sanner's precision design in enclosures and smart components. 5. Medical Device Development with Sanner's Global Footprint Sanner's global network gives Irish innovators unmatched scalability: - Bensheim, Germany - high-precision manufacturing HQ - Kunshan, China - world-class toolmaking and early industrialisation - Cambridge, UK - close-to-home device development for NI & ROI innovators - Sanner US - transatlantic commercialisation and FDA-ready pathways On St Patricks day, Ireland's Medtech future shines bright. Ireland is forging its future as one of the world's most connected, dynamic and innovative medtech hubs. Sanner stands ready to partner with innovators across the Emerald Isle - because in medtech, as in Ireland, success is built on partnership, expertise, and just a little bit of that legendary Irish luck. Lá Fhéile Pádraig sona duit ó Sanner Happy St Patrick's Day from Sanner.

Business Wire
Feb 26th, 2026
Dexcom Appoints Rick Osterloh to Board of Directors

Dexcom appoints Rick Osterloh to Board of Directors. SAN DIEGO-(BUSINESS WIRE)-DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio - Pixel phones, Google Nest smart home devices, and Fitbit wearables. Under his leadership, Google has integrated its portfolio to align and accelerate the company's advanced product capabilities across hardware, software and artificial intelligence. Mr. Osterloh brings to the Dexcom Board expertise in innovation oversight, strategic transactions and long-term strategic planning. "Rick is highly respected as one of the most influential technology product leaders of our time," said Jake Leach, president and CEO at Dexcom. "His insight into creating impactful, scalable products that integrate the latest innovative technologies aligns closely to Dexcom's vision for long-term product development. We look forward to benefiting from Rick's expertise as we advance our mission to improve the metabolic health for millions of people around the world." "I am honored to join the Dexcom Board at such an important moment for the company and for the future of metabolic health," said Osterloh. "Dexcom's leadership in biosensing aligns closely with my own passion for building and advancing technologies that address clear needs and improve people's lives. I look forward to partnering with the Board and executive team to execute on the company's compelling mission." About Rick Osterloh Mr. Rick Osterloh serves as Senior Vice President, Platform & Devices at Google, leading a unified group spanning Android, Google Play, Chrome, and Google's Devices & Services Portfolio (Pixel, Nest, Fitbit), a position he has held since 2016. Prior to this, Mr. Osterloh held additional senior leadership roles across consumer technologies. He served as President of Motorola Mobility from 2014-2016, and Senior Vice President, Product Management & GM Premium Products, Motorola Mobility from 2012-2014, overseeing global product strategy and operations during Motorola's transition under Google and subsequently Lenovo. Prior to this, Mr. Osterloh served as Vice President, Product & Design at Skype from 2010-2012 and held earlier roles at Motorola, Amazon, Kleiner Perkins Caulfield & Byers and Deloitte. Mr. Osterloh received bachelor's and master's degrees in Industrial Engineering from Stanford University. He also obtained an MBA from Stanford Graduate School of Business. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit www.dexcom.com. More News From DexCom, Inc. SAN DIEGO-( BUSINESS WIRE )-DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. D... SAN DIEGO-( BUSINESS WIRE )-Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results... SAN DIEGO-( BUSINESS WIRE )-Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks. Last year, Dexcom introduced AI-driven Smart Food Logging in Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United... DexCom, Inc. NASDAQ:DXCM Release Summary Release Versions

INACTIVE